Regorafenib_PIP

DRUG2 trials

Sponsors

Institut Gustave Roussy, The University Of Birmingham

Conditions

Newly diagnosed patients with metastatic (other than lung/pleura metastases only) Ewing sarcomaRhabdoyosarcoma

Phase 1

Phase Ib study of the combination of regorafenib with conventional chemotherapy for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma - REGO-INTER-EWING1

RecruitingCTIS2023-503322-39-00

Institut Gustave RoussyNewly diagnosed patients with metastatic (other than lung/pleura metastases only) Ewing sarcoma

Start: 2023-06-16Target: 26Updated: 2025-02-21

FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma

RecruitingCTIS2024-510579-40-00

The University Of BirminghamRhabdoyosarcoma

Start: 2020-10-07Target: 1185Updated: 2024-12-09